Showing results (551-560 of 575) with videos related to

Sort By:
Pageof 58
Life Sciences in Space Research|May 14, 2018
Solar particle event storm shelter requirements for missions beyond low Earth orbitL W Townsend, J H Adams, S R Blattnig, et al.
The Journal of Clinical Investigation|May 11, 2011
Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaqueMargalida Rotger, Judith Dalmau, Andri Rauch, et al.
The Journal of Experimental Medicine|June 25, 2008
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsetsClaude Sportès, Frances T Hakim, Sarfraz A Memon, et al.
JCI Insight|June 9, 2026
Reduced CCL/Be-specific CD4+ T cells in CCL3-deficient or peptide-MHC II CAR-T cell-treated miceMichael T Falta, Masoom Raza, Caley J Nevienski, et al.
The Journal of Clinical Investigation|September 14, 2020
Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patientsKazusa Ishii, Marie Pouzolles, Christopher D Chien, et al.
Nature|July 22, 2014
Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progressionNetanya G Sandler, Steven E Bosinger, Jacob D Estes, et al.
Plos Pathogens|December 16, 2014
Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activationAlexandra Schuetz, Claire Deleage, Irini Sereti, et al.
Nature Medicine|November 21, 2017
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapyTerry J Fry, Nirali N Shah, Rimas J Orentas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2020
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell TrialNirali N Shah, Steven L Highfill, Haneen Shalabi, et al.
Journal for Immunotherapy of Cancer|June 5, 2026
CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial resultsSara K Silbert, Flavia Gava, Bonnie Yates, et al.
Pageof 58